April 13, 2018 - By Stephen Andrade

Investors sentiment increased to Infinity in 2017 Q4. Its up Infinity, from 0.33 in 2017Q3. It improved, as 0 investors sold Provectus Biopharmaceuticals, Inc. shares while 0 reduced holdings. 2 funds opened positions while 0 raised stakes. 138,500 shares or 592.50% more from 20,000 shares in 2017Q3 were reported.
Focused Wealth Management accumulated 0% or 9,250 shares. Academy Mgmt Tx holds 0% or 20,000 shares in its portfolio. Budros Ruhlin & Roe owns 40,000 shares or 0% of their US portfolio.

The stock of PROVECTUS BIOPHARMACEUTICALS INC (OTCMKTS:PVCT) registered an increase of 0.11% in short interest. PVCT’s total short interest was 1.58M shares in April as published by FINRA. Its up 0.11% from 1.58 million shares, reported previously. With 1.46 million shares average volume, it will take short sellers 1 days to cover their PVCT’s short positions. The short interest to PROVECTUS BIOPHARMACEUTICALS INC’s float is 0.48%.

The stock 0.94% or $0 during the last trading session, reaching $0.07. It is down 0.00% since April 13, 2017 and is . It has underperformed by 11.55% the S&P500.

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. The company has market cap of $26.52 million. The Company’s prescription drug candidates includes PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. It currently has negative earnings. The firm is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.